Guardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 35%

 Guardant Health Inc (GH.O) said on Thursday a pivotal trial of its DNA blood test showed it detected 83% of colorectal cancers and 13% of advanced adenomas, a cancer precursor, but the results fell short of a rival stool-based test, sending the company's shares sharply lower.